Woodline Partners LP Sells 9,145 Shares of Vaxcyte, Inc. $PCVX

Key Points

• Woodline Partners LP has reduced its holdings in Vaxcyte, Inc. by 0.8%, now owning 1,111,777 shares valued at approximately $41.98 million.
• Vaxcyte reported a quarterly loss of ($1.22) EPS, missing analyst expectations, and analysts project earnings of -4.21 EPS for the current year.
• The stock has a market cap of $4.25 billion and a current consensus rating of "Buy" with an average price target of $121.75.

Woodline Partners LP cut its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 0.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,111,777 shares of the company's stock after selling 9,145 shares during the quarter. Woodline Partners LP owned 0.86% of Vaxcyte worth $41,981,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. AlphaQuest LLC acquired a new position in Vaxcyte during the 1st quarter worth approximately $33,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Vaxcyte during the 1st quarter worth approximately $35,000. Parallel Advisors LLC increased its position in Vaxcyte by 203.6% during the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock worth $61,000 after purchasing an additional 1,071 shares in the last quarter. IFP Advisors Inc increased its position in Vaxcyte by 376.4% during the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock worth $62,000 after purchasing an additional 1,306 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its position in Vaxcyte by 81.6% during the 1st quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company's stock worth $73,000 after purchasing an additional 867 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PCVX has been the subject of a number of research analyst reports. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research report on Friday. They set a "neutral" rating and a $38.00 price objective for the company. Cowen restated a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $106.25.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded down $0.48 during trading on Monday, reaching $31.69. The stock had a trading volume of 437,977 shares, compared to its average volume of 1,748,316. The firm's fifty day moving average is $33.16 and its 200 day moving average is $38.76. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06. The stock has a market cap of $4.11 billion, a price-to-earnings ratio of -7.72 and a beta of 1.04.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter in the prior year, the company earned ($1.10) EPS. On average, research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.